ID   A549rCDDP2000
AC   CVCL_RQ47
DR   cancercelllines; CVCL_RQ47
DR   Wikidata; Q54607064
RX   PubMed=28746345;
CC   Part of: Resistant Cancer Cell Line (RCCL) collection.
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0023 ! A-549
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 05-10-23; Version: 9
//
RX   PubMed=28746345; DOI=10.1371/journal.pone.0181081;
RA   Sarin N., Engel F., Kalayda G.V., Mannewitz M., Cinatl J. Jr.,
RA   Rothweiler F., Michaelis M., Saafan H., Ritter C.A., Jaehde U.,
RA   Frotschl R.;
RT   "Cisplatin resistance in non-small cell lung cancer cells is
RT   associated with an abrogation of cisplatin-induced G2/M cell cycle
RT   arrest.";
RL   PLoS ONE 12:E0181081-E0181081(2017).
//